Abstract:Treatment for Alzheimer’s disease (AD) has faced the difficult challenge of effectively targeting and clearing toxic and/or propagative species of protein, which together lead to pathology and neurodegeneration. Current evidence points to a cascade of aberrant proteostasis, generally involving cytotoxic tau pathology that is induced by misfolded Aβ oligomer [1,2,3]. A method for identifying antibodies to Aβ that are conformationally-selective to the toxic oligomer, and which also have relatively low affinity to either Aβ monomer or fibril, is thus a highly desired goal that holds significant promise for AD therapy [4]. We employ computational simulations, using molecular dynamics with standardized force-fields. An experimentally-validated structural model of a protofibrillar aggregate is globally biased away from its “native” conformation to be partially unfolded, using molecular dynamics with collective coordinates to yield a set of regions of contiguous primary sequence that are prone to be disordered upon an external challenge in an anomalous cellular environment. We hypothesize these weakly-stable regions are likely to be exposed in nascent protofibrils or oligomers, and that in this context they are present in an alternate conformation than they are either in the free monomer ensemble or in the context of the fibril. They thus constitute oligomer-specific epitope predictions. Oligomer-specific epitope predictions will be presented for Aβ. Cyclic peptides of these epitope primary sequences are both computationally and experimentally generated, which constitute antigenic targets. Clustering analysis, curvature, exposure to solvent, solubility, dihedral angle distribution, and Ramachandran angle distributions are all used to characterize the conformational properties of predicted epitopes, which quantify the distinction between the antigenic profile when presented in the context of the oligomer from that in either the monomer or fibril. A set of five oligomer-specific epitopes are proposed for Aβ. The computational epitope discovery approach has the potential to produce multiple Aβ oligomer-specific antibodies. Acknowledgements: ProMIS Neurosciences, the Canadian Institutes of Health Research and the Alberta Prion Research Institute. [1] Hadley, KC et al. eLife(2015). [2] Ittner LM, Gotz J, Nat Rev Neurosci (2011). [3] Vasconcelos B et al. Acta Neuropathol (2016). [4] Sevigny J, et al. Alzheimers Dement (2015).

Pharmacokinetic Modelling of Human Recombinant Protein, p75ECD-Fc: A Novel Therapeutic Approach for Treatment of Alzheimer’s Disease, in Serum and Tissue of Sprague Dawley Rats

Computational Analysis for the Rational Design of Anti-Amyloid Beta (ABeta) Antibodies

Pharmacokinetic and safety profile of PT109B, a novel multi-targeted compound against Alzheimer's disease

In vitro ADME, mouse pharmacokinetics of LD14b, and bioanalysis of a novel aβ 17β-HSD10 modulator for the treatment of Alzheimer's disease

Computational Epitope Prediction and Screening Precision Antibody Therapeutics for Alzheimer's Disease

An In Vitro and In Vivo Investigation

Recent Studies On Mechanisms Of New Drug Candidates For Alzheimer'S Disease Interacting With Amyloid-Beta Protofibrils Using Molecular Dynamics Simulations

A New Approach to Model Sporadic Alzheimer’s Disease by Intracerebroventricular Streptozotocin Injection in APP/PS1 Mice

Investigation of Plasma Metabolomics and Neurotransmitter Dysfunction in the Process of Alzheimer's Disease Rat Induced by Amyloid Beta 25-35

Pharmacodynamics in Alzheimer's Disease Model Rats of a Bifunctional Peptide with the Potential to Accelerate the Degradation and Reduce the Toxicity of Amyloid Β-Cu Fibrils.

Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease

Therapeutic potential of a TrkB agonistic antibody for Alzheimer's disease.

P2-315: A Novel Biotherapy for the Treatment of Alzheimer's Disease

Pharmacokinetics of seven major components in Aβ1-42-treated rats after oral administration of an aqueous extract of Curculiginis Rhizoma and Epimedii Folium

Computational analysis of novel drugs designed for use as acetylcholinesterase inhibitors and histamine H3 receptor antagonists for Alzheimer's disease by docking, scoring and de novo evolution

Pilot Study of the Reducing Effect on Amyloidosis in Vivo by Three FDA Pre-Approved Drugs Via the Alzheimer's APP 5' Untranslated Region.

Rational drug repurposing for alzheimer’s treatment using in-silico ligand and structure-based approaches

Preformulation Studies of a Stable PTEN-PDZ Lipopeptide Able to Cross an In Vitro Blood-Brain-Barrier Model as a Potential Therapy for Alzheimer's Disease

Effects of a Multimerized Recombinant Autoantibody Against Amyloid-β

P4-364 Rapid In-Vivo Assessment of Therapeutic Window of Two Γ-Secretase Inhibitors in Transgenic CRND8 Mice

A COMPUTATIONAL METHOD TO PREDICT DISEASE-SPECIFIC EPITOPES IN Aβ, AND ITS APPLICATION TO OLIGOMER-SELECTIVE ANTIBODIES FOR ALZHEIMER’S IMMUNOTHERAPY